Questcor Pharmaceuticals Inc

Questcor Pharmaceuticals — Citigroup conference (February 2012)

31 slides from Questcor Pharmaceuticals's conference presentation, Feb 27, 2012

  1. Slide 1: Questcor Pharmaceuticals - Citigroup, February 27, 2012

    NASDAQ: QCOR Exhibit 99.1 NASDAQ: QCOR February 27, 2012 Citigroup

  2. Slide 2: Safe Harbor Statement

    2 Safe Harbor Statement Note: Except for the historical information contained herein, this press release contains forward-looking statements that have been made pursuant to the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future financial performa

  3. Slide 3: Questcor: biopharmaceutical company whose product Acthar treats serious conditions

    3 A biopharmaceutical company whose product, Acthar, helps patients with serious, difficult-to-treat medical conditions Questcor A biopharmaceutical company whose product, Acthar, helps patients with serious, difficult-to-treat medical conditions

  4. Slide 4: Questcor Overview

    4 Flagship Product: • Profitable, cash flow positive, $226M** in cash, debt-free • 19 approved indications Key Markets*: • Multiple Sclerosis, Nephrotic Syndrome, Infantile Spasms • Several billion dollar market opportunity Strategy: • Continue to grow Acthar sales in each key market • Develop other

  5. Slide 5: Questcor Strategy - Pursue Acthar Markets

    5 Questcor Strategy - Pursue Acthar Markets Multiple Sclerosis (MS) Nephrotic Syndrome (NS) Infantile Spasms (IS) Systemic Lupus Erythematosus Multiple Sclerosis (MS) Nephrotic Syndrome (NS) Infantile Spasms (IS) Systemic Lupus Erythematosus

  6. Slide 6: Acthar and Multiple Sclerosis (MS)

    6 Neurodegenerative disorder Acute treatment for relapses Acthar and Multiple Sclerosis (MS) ACTHAR is approved for MS exacerbations, without reference to first line or second line use but is generally positioned as second line as a matter of marketing strategy. See http:// www.acthar.com/files/Acth

  7. Slide 7: MS Scripts - Record of Consistent Growth

    7 Notes: Historical trend information is not necessarily indicative of future results. Acthar is marketed for the on-label indication of MS exacerbations in adults, though the chart includes "Related Conditions" - diagnoses that are either alternative descriptions of the condition or are closely rel

  8. Slide 8: Monthly MS Scripts History

    8 Monthly MS Scripts History Notes: Historical trend information is not necessarily indicative of future results. Acthar is marketed for the on-label indication of MS exacerbations in adults, though the chart includes "Related Conditions" - diagnoses that are either alternative descriptions of the c

  9. Slide 9: Acthar and Nephrotic Syndrome (NS)

    9 Acthar and Nephrotic Syndrome (NS) • Characterized by excessive spilling of protein from the kidneys into the urine (proteinuria) • Can result in end-stage renal disease (ESRD), dialysis, transplant • Acthar is approved “to induce a diuresis or a remission of proteinuria in the nephrotic syndrome

  10. Slide 10: NS Scripts - Strong Q4 Growth

    10 Paid Rxs NS Scripts-Strong Q4 Growth Notes: Historical trend information is not necessarily indicative of future results. Chart includes "Related Conditions" - diagnoses that are either alternative descriptions of the condition or are closely related to the medical condition which is the focus of

  11. Slide 11: Acthar and Infantile Spasms (IS)

    11 • FDA approval 10/15/10 • Devastating, refractory form of childhood epilepsy • IS not responsive to standard anti-epileptic drugs • Unsuccessful treatment may leave infant with permanent developmental disabilities • Considered a medical emergency • Ultra-rare orphan disorder • About half of IS pa

  12. Slide 12: IS Scripts - Higher numbers in H2 2011

    12 • Acthar currently used to treat 40-50% of IS patients • Targeting select institutions • Significant variability in quarterly Rxs • Q4-2011 paid Rxs above historic range IS Scripts-Higher numbers in H2 2011 • Acthar currently used to treat 40-50% of IS patients • Targeting select institutions • S

  13. Slide 13: Systemic Lupus Erythematosus (Lupus)

    13 • High unmet need; difficult to treat • Serious health risk if unsuccessfully treated • Multiple on-label indications for Acthar – Exacerbations – Maintenance therapy – Lupus nephritis • Large patient population Systemic Lupus Erythematosus (Lupus) • High unmet need; difficult to treat • Serious

  14. Slide 14: Financials

    14 Profitable Debt Free Cash Flow Positive Financials Profitable Debt Free Cash Flow Positive

  15. Slide 15: Q4-2011 Financial Results

    15 Q4 – 2011 Q4 – 2010 Q4-2011 Financial Results • Fourth quarter vials shipped: 3,360 • Fourth quarter cash flow from operations: $31.4M • Channel inventory estimated to be within historic range • Medicaid reserves continue to appear adequate • No shares repurchased Record Net Sales (up 158%) and S

  16. Slide 16: 2011 Financial Results

    16 2011 2010 2011 Financial Results • Total vials shipped: 10,710 • Cash flow from operations: $85.6M • Channel inventory estimated to be within historic range • Medicaid reserves continue to appear adequate • 884,300 shares repurchased Record Net Sales (up 90%) and Solid Earnings (EPS up 124%) Net

  17. Slide 17: Questcor is Cash Flow Positive, Debt-free

    17 02/15/12 Questcor is Cash Flow Positive Debt-free balance sheet *After return of $78 million of cash to shareholders through share repurchases. Cash / ST Investments $226M* Accounts Receivable $44M Debt-free balance sheet *After return of $78 million of cash to shareholders through share repurcha

  18. Slide 18: Share Repurchases: 15 Million Shares

    • 2.2 Million Preferred share buyback • 13.2 Common share buyback • $78 million returned to shareholders in stock buybacks • 63.6 million shares currently outstanding • 4.3 million shares remain on buyback authorization Repurchased shares significantly improved EPS Share Repurchases: 15 Million Shar

  19. Slide 19: 2012 Preliminary Information

    19 • Operating expenses expected to be up in Q1-2012 20-25% over Q4-2011, increase again somewhat in Q2-2012, then level out for the remainder of 2012 • Paid Rxs January 2012 (estimated) – MS: 338 – NS: 72 – IS: 48 2012 Preliminary Information Notes: Paid Rx information based on internal estimates.

  20. Slide 20: How Does Acthar Work?

    20 How Does Acthar Work? • Acthar treats autoimmune conditions across a variety of organ systems (CNS, kidney, etc.) • Acthar appears to modulate the immune system and associated inflammatory response through binding to melanocortin receptors • The primary melanocortin peptide (ACTH) in Acthar binds

  21. Slide 21: Biosimilar Pathway Difficult/Impossible

    21 • Difficult/impossible to reverse engineer ACTHAR – Not well characterized • Complex pharmacology – Not well characterized • Clinical trial(s) required Biosimilar Pathway Difficult/Impossible • Difficult/impossible to reverse engineer ACTHAR – Not well characterized • Complex pharmacology – Not w

  22. Slide 22: Acthar Market Opportunity

    22 Market Rx Value Market Size Total $2B+ Acthar Market Opportunity MS $40-50K $1B+ NS $150-250K $1B+ IS $100-125K $100M Lupus Unknown Unknown Other Various Unknown

  23. Slide 23: NS Business Already Significant

    23 Market Approximate Annualized Net Sales Run Rate* Approximate Annualized Level of Business** NS Business Already Significant MS $145-160M $145-160M NS $60-70M $100-110M IS $40-50M $40-50M Note: Figures do not represent actual net sales ranges for the quarter or year ended December 31, 2011 * Figu

  24. Slide 24: Strategic Plan - Focus on the Embedded Pipeline in Acthar

    24 Strategic Plan- Focus on the Embedded Pipeline in Acthar • Expand NS promotion effort • Expand MS promotion effort • Maintain IS promotion effort • Develop pilot rheumatology promotion activity • Develop other markets for Acthar Acthar is its own pipeline with many other on-label indications and

  25. Slide 25: Sales Force Expansion - Preliminary Outlook for 2012

    25 Sales Force Expansion- Preliminary Outlook for 2012 Q1-12 Q2 Q3 Q4 Q1-13 Possible Rheumatology Possible Rheumatology Sales Pilot Sales Pilot Neuro Hiring & Neuro Hiring & Training Training Neuro Neuro Sizing & Sizing & Alignment Alignment Neph Hiring & Neph Hiring & Training Training Neph Sizing

  26. Slide 26: Investment Highlights

    26 Investment Highlights Acthar has sustainable competitive Acthar has sustainable competitive advantages-without FDA approval risk advantages-without FDA approval risk Acthar is approved for 19 indications-many Acthar is approved for 19 indications-many in large markets with sizable unmet need in l

  27. Slide 27: February 27, 2012 Citigroup

    February 27, 2012 Citigroup NASDAQ: QCOR February 27, 2012 February 27, 2012 Citigroup Citigroup NASDAQ: NASDAQ: QCOR QCOR

  28. Slide 28: ACTH is a Melanocortin Peptide Derived from POMC

    28 ACTH is a Melanocortin Peptide Derived from Pro-opiomelanocortin (POMC) in the Pituitary

  29. Slide 29: Affinity of Melanocortin Peptides and Distribution of Receptor Subtypes

    29 MCR Prevalent Tissue/Cells with Receptor Adapted from Gong 2011, Catania 2004, Schioth 1997 Affinity of Melanocortin Peptides and Distribution of Receptor Subtypes MC1R Podocytes Renal Mesangial Cells Endothelial Cells (Glomerular, Tubular, Vascular) Tubular Epithelial Cells Macrophages Melanocyt

  30. Slide 30: Affinity of Melanocortin Peptides and Distribution of Receptor Subtypes

    30 MCR Prevalent Tissue/Cells with Receptor Adapted from Gong 2011, Catania 2004, Schioth 1997 Affinity of Melanocortin Peptides and Distribution of Receptor Subtypes MC3R CNS Macrophages MC4R Podocytes Renal Mesangial Cells (?) Endothelial Cells (Glomerular, Tubular) Tubular Epithelial Cells CNS MC

  31. Slide 31: MOA of Acthar in NS

    31 MOA of Acthar in NS Adapted From Gong 2011 Acthar, Melanocortin Peptides Acthar, Melanocortin Peptides

Questcor Pharmaceuticals — Citigroup conference (February 2012) on 6ix